AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

AbbVie announced an update on their ongoing clinical study. The pharmaceutical giant is conducting a Phase 1b clinical study ...

Trump calls for API stockpile, OCOchem to scale up chemicals from carbon dioxide, Covestro to buy isocyanates plants, and ...

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today the newest addition to the SkinMedica(R) HA5(R) Hydra Collagen portfolio. Featuring the brand's proprietary HA5(R) Hydra Collagen ...

AbbVie Inc. has turned heads recently with a notable uptick in stock searches. Over the last month, its shares soared by +9.2 ...

Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics OperationsHer appointment brings over 30 years of strategic, commercial, and operational expertise in the ...

Evolus Inc. lost a third of its value after lower-than-expected second quarter results, reflecting weakened demand within the ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

Marjorie Taylor Greene (R-GA) has disclosed a new series of stock trades that highlight her interest in both high-growth ...

Over the past decade, AbbVie's shares have increased by 353.3%, or 16.3% annually, with dividends reinvested. That's ...